U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula 2C12H19NO3.H2O4S
Molecular Weight 548.647
Optical Activity ( + / - )
Defined Stereocenters 0 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TERBUTALINE SULFATE

SMILES

OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1.CC(C)(C)NCC(O)C2=CC(O)=CC(O)=C2

InChI

InChIKey=KFVSLSTULZVNPG-UHFFFAOYSA-N
InChI=1S/2C12H19NO3.H2O4S/c2*1-12(2,3)13-7-11(16)8-4-9(14)6-10(15)5-8;1-5(2,3)4/h2*4-6,11,13-16H,7H2,1-3H3;(H2,1,2,3,4)

HIDE SMILES / InChI
Molecular Formula H2O4S
Molecular Weight 98.078
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C12H19NO3
Molecular Weight 225.2842
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: Description was created based on several sources, including

Terbutaline is a relatively selective beta2-adrenergic bronchodilator that has little or no effect on alpha-adrenergic receptors. The drug has exerts a preferential effect on beta2-adrenergic receptors but stimulates beta-adrenergic receptors less selectively than relatively selective beta2-agonists. Terbutaline appears to have a greater stimulating effect on beta-receptors of the bronchial, vascular, and uterine smooth muscles (beta2 receptors) than on the beta-receptors of the heart (beta1 receptors). This drug relaxes smooth muscle and inhibits uterine contractions, but may also cause some cardiostimulatory effects and CNS stimulation. The pharmacologic effects of terbutaline are at least in part attributable to stimulation through beta-adrenergic receptors of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic- 3',5'- adenosine monophosphate (c-AMP). Increased c-AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells. Terbutaline is used for the prevention and reversal of bronchospasm in patients 12 years of age and older with reversible, obstructive airway disease, as well as symptomatic management of reversible bronchospasm associated with bronchitis and emphysema. Also used acute IV and sub-Q therapy in selected women to inhibit uterine contractions in preterm labor (tocolysis) and prolong gestation when beneficial.

CNS Activity

CNS Active
3913
Curator's Comment: may cause some cardiostimulatory effects and CNS stimulation.

Originator

Approval Year

1974
168
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2678
 3.16 µM [EC50]
Partial Agonist
290
 2.3 µM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Approved
8429
Terbutaline SULFATE

Approved Use

indicated for the prevention and reversal of bronchospasm in patients 12 years of age and older with asthma and reversible bronchospasm associated with bronchitis and emphysema.

Launch Date

2014
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
24 nM
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/2706188/
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TERBUTALINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
148.6 nM × h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/2706188/
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TERBUTALINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
13.7 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/2706188/
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TERBUTALINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
2 mg single, transdermal
Overdose
Dose: 2 mg
Route: transdermal
Route: single
Dose: 2 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/8400938
unhealthy, 15 years
n = 1
Health Status: unhealthy
Age Group: 15 years
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/8400938
Other AEs: Tachycardia, Systolic murmur...
Other AEs:
Tachycardia (1 patient)
Systolic murmur (1 patient)
Tremor (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/8400938
50 mg single, oral
Overdose
Dose: 50 mg
Route: oral
Route: single
Dose: 50 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/7793711
pregnant, 21 years
n = 1
Health Status: pregnant
Age Group: 21 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/7793711
Other AEs: Abdominal pain, Jitteriness...
Other AEs:
Abdominal pain (1 patient)
Jitteriness (1 patient)
Palpitations (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/7793711
500 mg single, oral
Overdose
Dose: 500 mg
Route: oral
Route: single
Dose: 500 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/3692499
unhealthy, 22 years
Health Status: unhealthy
Age Group: 22 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/3692499
Other AEs: Nausea, Tachycardia...
Other AEs:
Nausea (1 patient)
Tachycardia (1 patient)
Tremor (1 patient)
Hyperglycemia (1 patient)
Hypokalemia (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/3692499
2.5 mg single, subcutaneous
Overdose
Dose: 2.5 mg
Route: subcutaneous
Route: single
Dose: 2.5 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/6102210
pregnant, 35 years
n = 1
Health Status: pregnant
Age Group: 35 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/6102210
Other AEs: Tachycardia...
Other AEs:
Tachycardia (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/6102210
10 mg 3 times / day multiple, oral
Highest studied dose
Dose: 10 mg, 3 times / day
Route: oral
Route: multiple
Dose: 10 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/2806513
unhealthy, 56 years (range: 44-68 years)
n = 12
Health Status: unhealthy
Condition: bronchial asthma
Age Group: 56 years (range: 44-68 years)
Sex: M+F
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/2806513
Other AEs: Tremor, Palpitation...
Other AEs:
Tremor
Palpitation
Sources:
https://pubmed.ncbi.nlm.nih.gov/2806513
10 ug/kg single, intravenous (starting)
Dose: 10 ug/kg
Route: intravenous
Route: single
Dose: 10 ug/kg
Sources:
https://pubmed.ncbi.nlm.nih.gov/10891825
unhealthy, 9.1 years
n = 29
Health Status: unhealthy
Condition: severe asthma
Age Group: 9.1 years
Sex: M+F
Population Size: 29
Sources:
https://pubmed.ncbi.nlm.nih.gov/10891825
Other AEs: Cardiotoxicity...
Other AEs:
Cardiotoxicity (3 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/10891825
AEs

AEs

AESignificanceDosePopulation
Systolic murmur 1 patient
2 mg single, transdermal
Overdose
Dose: 2 mg
Route: transdermal
Route: single
Dose: 2 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/8400938
unhealthy, 15 years
n = 1
Health Status: unhealthy
Age Group: 15 years
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/8400938
Tachycardia 1 patient
2 mg single, transdermal
Overdose
Dose: 2 mg
Route: transdermal
Route: single
Dose: 2 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/8400938
unhealthy, 15 years
n = 1
Health Status: unhealthy
Age Group: 15 years
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/8400938
Tremor 1 patient
2 mg single, transdermal
Overdose
Dose: 2 mg
Route: transdermal
Route: single
Dose: 2 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/8400938
unhealthy, 15 years
n = 1
Health Status: unhealthy
Age Group: 15 years
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/8400938
Abdominal pain 1 patient
50 mg single, oral
Overdose
Dose: 50 mg
Route: oral
Route: single
Dose: 50 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/7793711
pregnant, 21 years
n = 1
Health Status: pregnant
Age Group: 21 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/7793711
Jitteriness 1 patient
50 mg single, oral
Overdose
Dose: 50 mg
Route: oral
Route: single
Dose: 50 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/7793711
pregnant, 21 years
n = 1
Health Status: pregnant
Age Group: 21 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/7793711
Palpitations 1 patient
50 mg single, oral
Overdose
Dose: 50 mg
Route: oral
Route: single
Dose: 50 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/7793711
pregnant, 21 years
n = 1
Health Status: pregnant
Age Group: 21 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/7793711
Hyperglycemia 1 patient
500 mg single, oral
Overdose
Dose: 500 mg
Route: oral
Route: single
Dose: 500 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/3692499
unhealthy, 22 years
Health Status: unhealthy
Age Group: 22 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/3692499
Hypokalemia 1 patient
500 mg single, oral
Overdose
Dose: 500 mg
Route: oral
Route: single
Dose: 500 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/3692499
unhealthy, 22 years
Health Status: unhealthy
Age Group: 22 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/3692499
Nausea 1 patient
500 mg single, oral
Overdose
Dose: 500 mg
Route: oral
Route: single
Dose: 500 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/3692499
unhealthy, 22 years
Health Status: unhealthy
Age Group: 22 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/3692499
Tachycardia 1 patient
500 mg single, oral
Overdose
Dose: 500 mg
Route: oral
Route: single
Dose: 500 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/3692499
unhealthy, 22 years
Health Status: unhealthy
Age Group: 22 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/3692499
Tremor 1 patient
500 mg single, oral
Overdose
Dose: 500 mg
Route: oral
Route: single
Dose: 500 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/3692499
unhealthy, 22 years
Health Status: unhealthy
Age Group: 22 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/3692499
Tachycardia 1 patient
2.5 mg single, subcutaneous
Overdose
Dose: 2.5 mg
Route: subcutaneous
Route: single
Dose: 2.5 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/6102210
pregnant, 35 years
n = 1
Health Status: pregnant
Age Group: 35 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/6102210
Palpitation
10 mg 3 times / day multiple, oral
Highest studied dose
Dose: 10 mg, 3 times / day
Route: oral
Route: multiple
Dose: 10 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/2806513
unhealthy, 56 years (range: 44-68 years)
n = 12
Health Status: unhealthy
Condition: bronchial asthma
Age Group: 56 years (range: 44-68 years)
Sex: M+F
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/2806513
Tremor
10 mg 3 times / day multiple, oral
Highest studied dose
Dose: 10 mg, 3 times / day
Route: oral
Route: multiple
Dose: 10 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/2806513
unhealthy, 56 years (range: 44-68 years)
n = 12
Health Status: unhealthy
Condition: bronchial asthma
Age Group: 56 years (range: 44-68 years)
Sex: M+F
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/2806513
Cardiotoxicity 3 patients
10 ug/kg single, intravenous (starting)
Dose: 10 ug/kg
Route: intravenous
Route: single
Dose: 10 ug/kg
Sources:
https://pubmed.ncbi.nlm.nih.gov/10891825
unhealthy, 9.1 years
n = 29
Health Status: unhealthy
Condition: severe asthma
Age Group: 9.1 years
Sex: M+F
Population Size: 29
Sources:
https://pubmed.ncbi.nlm.nih.gov/10891825
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
1612

OverviewOther

Other InhibitorOther SubstrateOther Inducer
Cav1.2
4
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
Cav1.2
49
hERG
1647
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:9449
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:9449
ChemicalBook
CB02131227
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB02131227
MolPort
MolPort-003-850-418
https://www.molport.com/shop/molecule-link/MolPort-003-850-418
eMolecules
27524076
https://www.emolecules.com/cgi-bin/more?vid=27524076
eMolecules
31228026
https://www.emolecules.com/cgi-bin/more?vid=31228026
PubMed

PubMed

TitleDatePubMed
Enhanced responsiveness of the myocardial beta-adrenoceptor-adenylate cyclase system in the perfused rat heart (I).
1998 Oct
Functional, biochemical and molecular biological evidence for a possible beta(3)-adrenoceptor in human near-term myometrium.
2000 Aug
beta(2)-adrenoceptor agonist suppresses renal tumour necrosis factor and enhances interleukin-6 gene expression induced by endotoxin.
2000 Dec
L-Dopa uptake and dopamine production in proximal tubular cells are regulated by beta(2)-adrenergic receptors.
2000 Jul
Systemic capillary leak syndrome preceding plasma cell leukaemia.
2001
Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants.
2001
Alveolar epithelial type II cell: defender of the alveolus revisited.
2001
Treatment of fetal congenital complete heart block with maternal administration of beta-sympathomimetics (terbutaline): a case report.
2001
Long-acting beta-agonist treatment in patients with persistent asthma already receiving inhaled corticosteroids.
2001
Choices of therapy for exercise-induced asthma in children.
2001
Inhaled short-acting beta2-agonists versus ipratropium for acute exacerbations of chronic obstructive pulmonary disease.
2001
Nocturnal asthma uncontrolled by inhaled corticosteroids: theophylline or long-acting beta2 agonists?
2001
Profile of ligand binding to the porcine beta2-adrenergic receptor.
2001 Apr
Glucocorticoid enhances the response of type II cells from newborn rats to surfactant secretagogues.
2001 Apr 30
Improved preparative-scale. continuous, free-flow electrophoretic separation of the enantiomers of terbutaline utilizing equal-but-opposite enantiomer mobilities.
2001 Aug
Pharmacological similarities and differences between beta2-agonists.
2001 Aug
Off-label prescribing and the standard of care.
2001 Aug 20
Regulation of SP-B and SP-C secretion in rat type II cells in primary culture.
2001 Dec
Quantitative determination of clenbuterol, salbutamol and tulobuterol enantiomers by capillary electrophoresis.
2001 Feb
Beta1-adrenergic agonist is a potent stimulator of alveolar fluid clearance in hyperoxic rat lungs.
2001 Feb
Intraocular pressure-lowering activity and in vivo disposition of dipivalyl terbutalone in rabbits.
2001 Feb
Blunted cardiac responses to receptor activation in subjects with Thr164Ile beta(2)-adrenoceptors.
2001 Feb 27
A single bout of exercise induces beta-adrenergic desensitization in human adipose tissue.
2001 Jan
Brittle asthma: a separate clinical phenotype of asthma?
2001 Jan-Mar
The effect of the beta(2) adrenoceptor gene Thr164Ile polymorphism on human adipose tissue lipolytic function.
2001 Jul
Attenuation of insulin resistance by chronic beta2-adrenergic agonist treatment possible muscle specific contributions.
2001 Jun 22
On-demand relief treatment for asthma.
2001 Jun 9
The effectiveness of high-dose inhaled budesonide therapy in the treatment of acute asthma exacerbations in children.
2001 Mar
The essential role of cytosolic Cl- in Ca2+ regulation of an amiloride-sensitive channel in fetal rat pneumocyte.
2001 Mar 1
Tocolysis with nifedipine or beta-adrenergic agonists: a meta-analysis.
2001 May
The oxytocin antagonist atosiban versus the beta-agonist terbutaline in the treatment of preterm labor. A randomized, double-blind, controlled study.
2001 May
Effects of terbutaline on NGF formation in allergic inflammation of the rat.
2001 May
Pharmacological characterization of KUR-1246, a selective uterine relaxant.
2001 May
Alveolar epithelial barrier functions in ventilated perfused rabbit lungs.
2001 May
Efficacy of 'functional relaxation' in comparison to terbutaline and a 'placebo relaxation' method in patients with acute asthma. A randomized, prospective, placebo-controlled, crossover experimental investigation.
2001 May-Jun
Hypoxia reduces alveolar epithelial sodium and fluid transport in rats: reversal by beta-adrenergic agonist treatment.
2001 Nov
Beta-adrenoceptor signaling in the developing brain: sensitization or desensitization in response to terbutaline.
2001 Nov 26
Sulindac to prevent recurrent preterm labor: a randomized controlled trial.
2001 Oct
Fatal adverse drug events: the paradox of drug treatment.
2001 Oct
Regulation of fetal cardiac and hepatic beta-adrenoceptors and adenylyl cyclase signaling: terbutaline effects.
2001 Oct
Fast enantiomeric separation of basis drugs by electrokinetic chromatography. Application to the quantitation of terbutaline in a pharmaceutical preparation.
2001 Sep
A cost-effectiveness study comparing the as-needed use of formoterol (Oxis) and terbutaline (Bricanyl) in patients with moderate to severe asthma.
2001 Sep
A single dose of nebulized budesonide decreases exhaled nitric oxide in children with acute asthma.
2001 Sep
An advanced and detailed in vitro validation procedure for the radiolabeling of carrier-free terbutaline sulphate dry powder.
2001 Summer
Pulmonary clearance rate of two chemically different forms of inhaled pertechnetate.
2001 Summer
Patents

Patents

JP2009526755A
447
JP2011510954A
143
JP4616993B2
12
JP4796732B2
9
JPH00597707A
9
JPH01197444A
15

Sample Use Guides

In Vivo Use Guide
Usual Adult Dose for Asthma - Maintenance Tablets: 5 mg orally 3 times a day at 6 hour intervals during waking hours. May decrease to 2.5 mg/dose if side effects are pronounced. Do not exceed 15 mg in 24 hours. Inhalation aerosol: 2 inhalations separated by 60 seconds every 4 to 6 hours. Do not repeat more often than every 4 to 6 hours. Usual Adult Dose for Asthma - Acute Inhalation aerosol: 2 inhalations separated by 60 seconds every 4 to 6 hours. Do not repeat more often than every 4 to 6 hours. Subcutaneous Injection: 0.25 mg into the lateral deltoid area. A second 0.25 mg dose can be administered in 15 to 30 minutes if needed. Do not exceed 0.5 mg in 4 hours. Continuous intravenous infusion: 0.08 to 6 mcg/kg/min.
Route of Administration: Other
In Vitro Use Guide
Terbutaline elicited a relaxation response in isolated rat's tracheal smooth muscle at a dose of 10(-6) M or more
Substance Class Chemical
Created
by admin
on Fri Dec 15 17:58:22 GMT 2023
Edited
by admin
on Fri Dec 15 17:58:22 GMT 2023
Record UNII
576PU70Y8E
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TERBUTALINE SULFATE
EP   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN  
Official Name English
TERBUTALINE SULFATE [MART.]
Common Name English
TERBUTALINE SULFATE [VANDF]
Common Name English
TERBUTALINE SULFATE [EP MONOGRAPH]
Common Name English
TERBUTALINE SULPHATE
Common Name English
TERBUTALINE SULFATE [ORANGE BOOK]
Common Name English
KWD 2019
Code English
TERBUTALINE SULFATE [MI]
Common Name English
KWD-2019
Code English
(±)-.ALPHA.-((TERT-BUTYLAMINO)METHYL)-3,5-DIHYDROXYBENZYL ALCOHOL SULFATE (2:1) (SALT)
Common Name English
TERBUTALINE SULFATE [USP-RS]
Common Name English
BRETHINE
Brand Name English
Terbutaline sulfate [WHO-DD]
Common Name English
NSC-757336
Code English
BRETHAIRE
Brand Name English
TERBUTALINE SULFATE [USP MONOGRAPH]
Common Name English
TERBUTALINE SULFATE [JAN]
Common Name English
TERBUTALINE SULFATE [USAN]
Common Name English
1,3-BENZENEDIOL, 5-(2-((1,1-DIMETHYLETHYL)AMINO)-1-HYDROXYETHYL)-, SULFATE (2:1) (SALT)
Common Name English
TERBUTALINE SULFATE [EP IMPURITY]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C48149
Created by admin on Fri Dec 15 17:58:22 GMT 2023 , Edited by admin on Fri Dec 15 17:58:22 GMT 2023
NCI_THESAURUS C319
Created by admin on Fri Dec 15 17:58:22 GMT 2023 , Edited by admin on Fri Dec 15 17:58:22 GMT 2023
Code System Code Type Description
SMS_ID
100000084794
Created by admin on Fri Dec 15 17:58:22 GMT 2023 , Edited by admin on Fri Dec 15 17:58:22 GMT 2023
PRIMARY
MERCK INDEX
m10572
Created by admin on Fri Dec 15 17:58:22 GMT 2023 , Edited by admin on Fri Dec 15 17:58:22 GMT 2023
PRIMARY Merck Index
NSC
757336
Created by admin on Fri Dec 15 17:58:22 GMT 2023 , Edited by admin on Fri Dec 15 17:58:22 GMT 2023
PRIMARY
NCI_THESAURUS
C47748
Created by admin on Fri Dec 15 17:58:22 GMT 2023 , Edited by admin on Fri Dec 15 17:58:22 GMT 2023
PRIMARY
CAS
23031-32-5
Created by admin on Fri Dec 15 17:58:22 GMT 2023 , Edited by admin on Fri Dec 15 17:58:22 GMT 2023
PRIMARY
DRUG BANK
DBSALT000297
Created by admin on Fri Dec 15 17:58:22 GMT 2023 , Edited by admin on Fri Dec 15 17:58:22 GMT 2023
PRIMARY
ECHA (EC/EINECS)
245-386-3
Created by admin on Fri Dec 15 17:58:22 GMT 2023 , Edited by admin on Fri Dec 15 17:58:22 GMT 2023
PRIMARY
ChEMBL
CHEMBL1760
Created by admin on Fri Dec 15 17:58:22 GMT 2023 , Edited by admin on Fri Dec 15 17:58:22 GMT 2023
PRIMARY
RXCUI
10369
Created by admin on Fri Dec 15 17:58:22 GMT 2023 , Edited by admin on Fri Dec 15 17:58:22 GMT 2023
PRIMARY RxNorm
EPA CompTox
DTXSID3045437
Created by admin on Fri Dec 15 17:58:22 GMT 2023 , Edited by admin on Fri Dec 15 17:58:22 GMT 2023
PRIMARY
FDA UNII
576PU70Y8E
Created by admin on Fri Dec 15 17:58:22 GMT 2023 , Edited by admin on Fri Dec 15 17:58:22 GMT 2023
PRIMARY
EVMPD
SUB04724MIG
Created by admin on Fri Dec 15 17:58:22 GMT 2023 , Edited by admin on Fri Dec 15 17:58:22 GMT 2023
PRIMARY
DAILYMED
576PU70Y8E
Created by admin on Fri Dec 15 17:58:22 GMT 2023 , Edited by admin on Fri Dec 15 17:58:22 GMT 2023
PRIMARY
PUBCHEM
31620
Created by admin on Fri Dec 15 17:58:22 GMT 2023 , Edited by admin on Fri Dec 15 17:58:22 GMT 2023
PRIMARY
RS_ITEM_NUM
1643500
Created by admin on Fri Dec 15 17:58:22 GMT 2023 , Edited by admin on Fri Dec 15 17:58:22 GMT 2023
PRIMARY
Related Record Type Details
Structure of TERBUTALINE
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of 3,5-DIHYDROXYBENZOIC ACID
IMPURITY -> PARENT
sum of impurities other than C: not more than twice the area of the principal peak in the chromatogram obtained with reference solution (b) (0.4 per cent)
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of TERBUTALONE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 2-(BENZYL(TERT-BUTYL)AMINO)-1-(3,5-DIHYDROXYPHENYL)ETHAN-1-ONE
IMPURITY -> PARENT
sum of impurities other than C: not more than twice the area of the principal peak in the chromatogram obtained with reference solution (b) (0.4 per cent)
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
Structure of TERBUTALINE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966